Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $86

Cytokinetics, Incorporated +1.47% Post

Cytokinetics, Incorporated

CYTK

69.00

69.00

+1.47%

0.00% Post

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ: CYTK) with a Buy and raises the price target from $60 to $86.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via